Wegovy at 8 Weeks: What Do the Results Actually Look Like?

Why do week-eight results differ so much between people?

Eight weeks is still early in the Wegovy journey, and the variation people report online spans anything from a couple of kilograms lost to noticeably different clothing sizes. The main reason is timing: the standard Wegovy titration schedule begins at 0.25mg for four weeks, then steps to 0.5mg. At week eight you are finishing only your second dose level. The maintenance dose of 2.4mg is typically not reached until around week 17 at the earliest, and the bulk of trial-reported weight loss accumulates across many months at that higher dose.

Individual biology adds another layer. Genetics, starting weight, metabolic rate, gut motility and how severely nausea is affecting food intake all shift the numbers. Someone who feels too unwell to eat much during dose increases may show a faster early drop; someone tolerating the medicine smoothly may see a steadier, more gradual trend. Neither pattern predicts long-term outcomes reliably. The STEP 1 trial (the large phase-three study published in the New England Journal of Medicine) ran for 68 weeks, not eight, precisely because meaningful results require time at therapeutic doses.

It is also worth knowing that some people do not register much on the scales in weeks one to eight even while their appetite is genuinely suppressed. That appetite shift matters, it is the mechanism doing its work, even if the number has not caught up yet.

What does early weight loss at eight weeks actually look like in practice?

If you are curious how the first couple of weeks felt for others, the week-one experience is often dominated by side effects rather than weight change. By weeks two to four, appetite tends to quiet noticeably for most people, and if you want to understand what that early appetite shift can look like, reading about what people notice at the two-week point gives a useful sense of how quickly changes can begin. The changes visible by week eight typically fall somewhere between 2% and 5% of starting body weight across the trial population at low doses, though this figure is not specifically reported at the eight-week mark in published data (the trial timepoints are longer) so treat any precise claim you read as an approximation.

What is more consistently reported at this stage is reduced hunger between meals, smaller portion sizes feeling satisfying, and for some people a changed relationship with food cravings. These behavioural shifts are the early signal that the medicine is working as intended, even before major weight change is visible. If you want a fuller picture of how results typically develop across the first few weeks, the timeline for Wegovy to take effect covers that progression in detail.

We know this stage can feel discouraging. Eight weeks is long enough to be committed and short enough to still be wondering whether it is going to work, and that uncertainty is genuinely hard to sit with.

Are side effects at week eight a sign something is wrong?

Nausea, constipation, loose stools, reflux and fatigue are all listed by the NHS on their semaglutide medicines page as common effects, most pronounced during dose increases. Week eight lands right in the period when those increases are happening, so symptoms peaking at this point is typical, not alarming. They usually ease within a few days to two weeks of each new dose level.

That said, some symptoms warrant prompt medical attention: severe and persistent stomach pain, especially if it radiates toward the back, should not be left unassessed, this is the pattern associated with pancreatitis, which the MHRA flagged in a Drug Safety Update in January 2026 as a known but infrequent risk with GLP-1 medicines. Gallbladder pain, signs of dehydration from repeated vomiting, or any allergic reaction are also reasons to contact a healthcare professional without delay. Side effects that feel manageable should be reported to your prescriber anyway; dose-timing adjustments or practical tips often make a real difference. Report anything unexpected via the MHRA's Yellow Card scheme.

If results feel slow, what comes next?

Eight weeks is genuinely too early to judge whether Wegovy will work for you. The dose increases still to come are substantial (from 0.5mg to 1.0mg, then 1.7mg, then 2.4mg) and each step tends to deepen appetite suppression. The evidence for semaglutide 2.4mg is built across 68 weeks of treatment, not eight, and the weight lost in the early months is a small fraction of the total that trial participants achieved by the end. The six-week mark often looks similar to week eight for the same reason: not enough time at a meaningful dose yet.

Lifestyle factors continue to matter alongside the medicine. Protein intake, hydration, sleep and regular movement all support the results that semaglutide makes possible. Your prescriber is the right person to discuss whether your progress is on track, whether any dose adjustment is appropriate, and what realistic targets look like for your starting point. Pricing information for private treatment is set out clearly on the Wegovy cost page if that is part of your thinking at this stage.

If you are not yet on treatment and want to understand whether Wegovy could be right for you, a free consultation with a GPhC-registered prescriber at nume is the place to start. Start your free consultation and a real clinician will review your details the same day.